Huaising C Ko1, Paul M Harari1, Shuai Chen2, Aaron M Wieland3, Menggang Yu2, Andrew M Baschnagel1, Randall J Kimple1, Matthew E Witek1. 1. Department of Human Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison. 2. Department of Biostatistics and Medical Informatics, Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison. 3. Division of Otolaryngology and Head and Neck Surgery, Department of Surgery, Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison.
Abstract
Importance: Radiotherapy (RT)-based organ preservation approaches for patients with advanced laryngeal cancer have been established stepwise through prospective randomized clinical trials. However, broad adoption of these approaches has stimulated discussion about long-term results challenging their applicability in a heterogeneous patient population, most recently for patients with T3 disease. Objective: To define outcomes in patients with clinical T3N0M0 glottic laryngeal cancer treated with definitive surgical and RT-based approaches. Design, Setting, and Participants: This retrospective cohort study included patients treated from January 1, 2004, through December 31, 2013, with a median follow-up time of 58 months (range, 0-126.6 months) in the National Cancer Database. Of the 4003 patients with T3N0M0 disease, 2622 received definitive therapy defined by the study protocol. Data were obtained from the clinical oncology database sourced from hospital registry data that are collected from more than 1500 Commission on Cancer-accredited facilities. Data were analyzed from September 14, 2016, through April 24, 2017. Interventions: Radiotherapy, chemoradiotherapy, surgery, surgery and RT, or surgery and chemoradiotherapy. Main Outcomes and Measures: Five-year overall survival (OS). Results: A total of 2622 patients (2251 men [85.9%] and 371 women [14.1%]; median age, 64 years [range, 19-90 years]) were included in the analytic cohort. In the overall patient cohort, the adjusted 5-year survival probability was 53%. No statistical differences were observed between the primary surgery (53%; 95% CI, 48%-57%) and primary RT (54%; 95% CI, 52%-57%) cohorts. In multivariate analysis, patient factors associated with decreased OS included age (hazard ratio [HR], 1.04; 95% CI, 1.03-1.04), insurance status (HR, 1.26; 95% CI, 1.06-1.50), and increasing comorbidity (HR, 1.20; 95% CI, 1.02-1.42). Conclusions and Relevance: Current management of T3N0M0 glottic laryngeal cancer relies largely on RT-based organ preservation approaches. The present study substantiates randomized clinical trial data supporting the use of RT-based organ preservation approaches for patients with T3N0M0 glottic laryngeal cancer without compromising OS.
Importance: Radiotherapy (RT)-based organ preservation approaches for patients with advanced laryngeal cancer have been established stepwise through prospective randomized clinical trials. However, broad adoption of these approaches has stimulated discussion about long-term results challenging their applicability in a heterogeneous patient population, most recently for patients with T3 disease. Objective: To define outcomes in patients with clinical T3N0M0 glottic laryngeal cancer treated with definitive surgical and RT-based approaches. Design, Setting, and Participants: This retrospective cohort study included patients treated from January 1, 2004, through December 31, 2013, with a median follow-up time of 58 months (range, 0-126.6 months) in the National Cancer Database. Of the 4003 patients with T3N0M0 disease, 2622 received definitive therapy defined by the study protocol. Data were obtained from the clinical oncology database sourced from hospital registry data that are collected from more than 1500 Commission on Cancer-accredited facilities. Data were analyzed from September 14, 2016, through April 24, 2017. Interventions: Radiotherapy, chemoradiotherapy, surgery, surgery and RT, or surgery and chemoradiotherapy. Main Outcomes and Measures: Five-year overall survival (OS). Results: A total of 2622 patients (2251 men [85.9%] and 371 women [14.1%]; median age, 64 years [range, 19-90 years]) were included in the analytic cohort. In the overall patient cohort, the adjusted 5-year survival probability was 53%. No statistical differences were observed between the primary surgery (53%; 95% CI, 48%-57%) and primary RT (54%; 95% CI, 52%-57%) cohorts. In multivariate analysis, patient factors associated with decreased OS included age (hazard ratio [HR], 1.04; 95% CI, 1.03-1.04), insurance status (HR, 1.26; 95% CI, 1.06-1.50), and increasing comorbidity (HR, 1.20; 95% CI, 1.02-1.42). Conclusions and Relevance: Current management of T3N0M0 glottic laryngeal cancer relies largely on RT-based organ preservation approaches. The present study substantiates randomized clinical trial data supporting the use of RT-based organ preservation approaches for patients with T3N0M0 glottic laryngeal cancer without compromising OS.
Authors: Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson Journal: N Engl J Med Date: 1991-06-13 Impact factor: 91.245
Authors: Henry T Hoffman; Kimberly Porter; Lucy H Karnell; Jay S Cooper; Randall S Weber; Corey J Langer; Kie-Kian Ang; Greer Gay; Andrew Stewart; Robert A Robinson Journal: Laryngoscope Date: 2006-09 Impact factor: 3.325
Authors: Surbhi Grover; Samuel Swisher-McClure; Nandita Mitra; Jiaqi Li; Roger B Cohen; Peter H Ahn; John N Lukens; Ara A Chalian; Gregory S Weinstein; Bert W O'Malley; Alexander Lin Journal: Int J Radiat Oncol Biol Phys Date: 2015-07-01 Impact factor: 7.038
Authors: F Christopher Holsinger; Merrill S Kies; Eduardo M Diaz; Ann M Gillenwater; Jan S Lewin; Lawrence E Ginsberg; Bonnie S Glisson; Adam S Garden; Nebil Ark; Heather Y Lin; J Jack Lee; Adel K El-Naggar; Waun Ki Hong; Dong M Shin; Fadlo R Khuri Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Maha Al-Gilani; S Andrew Skillington; Dorina Kallogjeri; Bruce Haughey; Jay F Piccirillo Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-10-01 Impact factor: 6.223
Authors: Adam R Burr; Paul M Harari; Alyx M Haasl; Aaron M Wieland; Justine Y Bruce; Randall J Kimple; Gregory K Hartig; Timothy M McCulloch; Matthew E Witek Journal: Head Neck Date: 2020-02-14 Impact factor: 3.147